Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street Zen

Zevra Therapeutics (NASDAQ:ZVRA) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

A number of other analysts have also issued reports on ZVRA. JMP Securities decreased their price target on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 13th. HC Wainwright initiated coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 price objective on the stock. Cantor Fitzgerald lifted their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Thursday, July 10th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Zevra Therapeutics in a research note on Saturday, September 27th. Finally, Zacks Research lowered Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Zevra Therapeutics Stock Down 2.9%

Shares of NASDAQ:ZVRA opened at $10.69 on Friday. The stock’s 50-day moving average price is $9.39 and its two-hundred day moving average price is $9.11. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52. Zevra Therapeutics has a 12-month low of $6.19 and a 12-month high of $13.16. The firm has a market cap of $600.03 million, a price-to-earnings ratio of -50.90 and a beta of 1.49.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($1.49). Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%.The business had revenue of $25.88 million during the quarter, compared to analyst estimates of $22.49 million. On average, research analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current year.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode acquired 5,000 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were bought at an average cost of $9.16 per share, for a total transaction of $45,800.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at $412,200. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Neil F. Mcfarlane sold 19,500 shares of Zevra Therapeutics stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $10.82, for a total value of $210,990.00. Following the sale, the chief executive officer owned 222,016 shares in the company, valued at $2,402,213.12. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Woodline Partners LP grew its position in shares of Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after acquiring an additional 476,032 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after acquiring an additional 550,000 shares in the last quarter. Rubric Capital Management LP grew its position in shares of Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after acquiring an additional 740,584 shares in the last quarter. AIGH Capital Management LLC grew its position in shares of Zevra Therapeutics by 82.4% in the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after acquiring an additional 649,495 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Zevra Therapeutics by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock worth $10,948,000 after acquiring an additional 9,275 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.